David joined FIPRA as a Special Advisor for Healthcare in January 2020. David has extensive experience in global rare disease drug development, registration and policy development.
From 2017 to 2020, David was the co-chair of the EFPIA/EuropaBio Rare Disease Task Force leading the consolidated industry strategy to EU consultations on rare disease legislation. In addition, David has interacted directly and via Industry Organisation with Health Authorities on the development and implementation of regulatory policy.
David has held senior global positions in large pharma companies (Pharmacia, Novo Nordisk and Shire) as well as small biotech companies (Swedish Orphan International). Most recently David held the position of Head of EU and International Regulatory Policy & Intelligence at Shire.
David received his B.Sc. (Hons) in Biology from the University of Western Ontario (UWO), M.Sc. in Pharmacology from the University of Toronto and a PhD in Pharmacology from the UWO. David Speaks English and has a basic understanding of French and Swedish.